The road to commercialization in Africa: Lessons from developing the sickle-cell drug Niprisan

BMC International Health and Human Rights

Volumn 10, Issue SUPPL. 1, 2010, Pages

  Perampaladas, Kumar ^a   Masum, Hassan ^a   Kapoor, Andrew ^a   Shah, Ronak ^a   Daar, Abdallah S ^a   Singer, Peter A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; NIPRISAN; UNCLASSIFIED DRUG;

AFRICA; ARTICLE; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNDING; HUMAN; NIGERIA; PEDIATRIC HOSPITAL; PROFESSIONAL KNOWLEDGE; PUBLIC HEALTH; QUALITY CONTROL; SICKLE CELL ANEMIA; STANDARDIZATION; TRADITIONAL MEDICINE; UNITED STATES;

EID: 78650427987     PISSN: None     EISSN: 1472698X     Source Type: Journal    
DOI: 10.1186/1472-698X-10-S1-S11     Document Type: Article

References (38)

1. A Tough Transition. PA Singer K Berndtson C Shawn Tracy ERM Cohen H Masum AS Daar, Nature 2007 449 7159 160 163 10.1038/449160a 17851510
2. Tide turns for drug manufacturing in Africa. T Anderson, The Lancet 2010 375 9726 1597 1598 10.1016/S0140-6736(10)60687-3
3. Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines. W Kaplan R Laing, Washington, D.C.: World Bank Health, Nutrition and Population (HNP) Discussion Paper 2005
4. Natural Products as a Robust Source of New Drugs and Drug leads: Past Successes and Present Day Issues. GM Rishton, American Journal of Cardiology 2008 101 Suppl 43D 49D 10.1016/j.amjcard.2008.02.007 18474274
5. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. DK Ro EM Paradise M Ouellet KJ Fisher KL Newman JM Ndungu,, et al. Nature 2006 440 940 943 10.1038/nature04640 16612385
6. A gift from nature: the birth of the statins. A Endo, Nature Medicine 2008 14 10 1050 1052 10.1038/nm1008-1050 18841147
7. Trading on traditional medicines. P Basu, Nature Biotechnology 2004 22 3 263 265 10.1038/nbt0304-263 14990941
8. Traditional Medicine Strategy 2002-2005. World Health Organization, 2002 Geneva
9. Sustainable Production of Traditional Medicines in Africa. OA Osunderu, Appropriate Technologies for Environmental Protection in the Developing World Springer Science: Netherlands, EK Yanful, 2009 43 51 full-text
10. A broad view of commercially important southern African medicinal plants. BEV Wyk, Journal of Ethnopharmacology 2008 119 342 355 10.1016/j.jep.2008.05. 029 18577439
11. Herbal medicine research and global health: an ethical analysis. TJ Kaptchuk JC Tilburt, WHO Bulletin 2008 86 8 594 599
12. The commercial harvest of devils claw (Harpagophytum spp) in southern Africa: The devils in the details. D Cole KM Steward, Journal of Ethnopharmacology 2005 100 225 236 10.1016/j.jep.2005.07.004 16112533
13. Is there a role for traditional medicines in basic health services in Africa? A plea for a community perspective. S Geest van der, Tropical Medicine and International Health 1997 2 903 911 10.1046/j.1365-3156.1997.d01-410.x 9315049
14. Traditional Medicine Development for Medical and Dental Primary Health Care Delivery System in Africa. AA Elujoba OM Odeleye CM Ogunyemia, African Journal of Traditional, Complementary, and Alternative Medicines 2005 2 1 46 61
15. Africas Regional Initiative for Traditional Medicines. http://ritmanet.org/about.htm
16. Biotechnology R&D partnership for industrial innovation in Nigeria. J Adeoti A Adeoti, Technovation 2005 25 4 349 365 10.1016/S0166-4972(03)00151-2 (Pubitemid 40142441)
17. Pharmacotherapy in sickle cell disease - state of the art and future prospects. J Hankins Aygun, British Journal Hematology 2009 145 3 296 308 10.1111/j.1365-2141.2009.07602.x
18. Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. MH Steinberg, JAMA 2003 289 13 1645 1651 10.1001/jama.289.13.1645 12672732
19. Sickle Cell Anemia Report by Secretariat. World Health Organization, 2006 Geneva
20. Sickle cell disease related pain: crisis and conflict. KH Todd C Green VL Bonham Jr C Haywood Jr E Ivy, Journal of Pain 2006 7 7 453 8 10.1016/j.jpain.2006.05.004 16814684
21. Niprisan Case - a report for GenBenefit 2007. http://www.uclan.ac.uk/ health/schools/school-of-nursing/research-projects/files/health-genbenefit- nigerian-case.pdf
22. Some basic requirements for preparing an anti-sickling herbal medicine - NIPRISAN. SJ Ameh OO Obodozie EK Afolabi EO Oyedele TA Ache CE Onanuga MC Ibe US Inyang, African Journal of Pharmacy and Pharmacology. 2009 3 5 259 264
23. United States Patent Office No. 5,800,819.
24. Double-blind, placebo-controlled, randomized cross-over clinical trial of NIPRISAN in patients with sickle cell disorder. C Wambebe H Khamofu JA Momoh M Ekpeyong BS Audu SO Njoku,, et al. Phytomedicine 2001 8 4 252 261 10.1078/0944-7113-00040 11515714
25. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. WI Efemwonkiekie EA Turner T Asakura, British Journal of Hematology 2003 122 1001 1008 10.1046/j.1365-2141. 2003.04536.x (Pubitemid 37174622)
26. In vitro effects of Niprisan (Nix-0699): a naturally occurring, potent antisickling agent. WI Efemwonkiekie EA Turner T Asakura, British Journal of Hematology 2002 118 337 343 10.1046/j.1365-2141.2002.03593.x (Pubitemid 34779560)
27. Efficacy of NIPRISAN in the prophylactic management of patients with sickle cell disease. C Wambebe EA Bamgboye BO Bardu H Khamofu JA Momoh M Ekpeyong,, et al. Current Therapeutic Research 2001 62 26 34 10.1016/S0011-393X(01)80039-4 (Pubitemid 32493028)
28. Xechem Pharmaceuticals Nigeria Ltd. http://www.saharareporters.com/ article/xechem-pharmaceuticals-nigeria-ltd
29. Orphan drug legislation: lessons for neglected tropical diseases. S Villa A Compagni MR Reich, Int J Health Plann Manage 2009 24 1 27 42 Jan-Mar 10.1002/hpm.930 18435430
30. SEC Info - Xechem International - 10KSB For 12/31/06. http://www.webcitation.org/5klwFcPnj
31. SEC Info - Xechem International - 10KSB For 12/31/05. http://www.webcitation.org/5km18whar
32. Sickle cell drug mired in controversy. http://www.scidev.net/en/news/ sickle-cell-drug-mired-in-controversy.html
33. SEC Info Xechem International Inc 8-K For 7/5/07. http://www.webcitation. org/5km2aFuUc
34. Nigeria takes over sickle cell drug. http://www.scidev.net/en/news/ nigeria-takes-over-sickle-cell-drug.html
35. Bankruptcy leaves indigenous sickle cell treatment in jeopardy. http://www.scidev.net/en/news/bankruptcy-leaves-indigenous-sickle-cell- treatment.html
36. World Bank Group - Doing Business in Nigeria, Measuring Business Regulations. http://www.webcitation.org/5kolCUPXk
37. National Tropical Botanical Garden - Catharanthus roseus. http://www.ntbg.org/plants/plant-details.php?rid=413&plantid=2497
38. Developing ANDI, a novel approach to health product R&D in Africa. S Nwaka TB Ilunga JS Da Silva E Rial Verde D Hackley R De Vré T Mboya-Okeyo RG Ridley, PLoS Med 2010 7 6 1000293 Jun 29 10.1371/journal.pmed.1000293 20613865